Group 1 - Carlton Precious Inc. is undertaking a non-brokered private placement to raise up to $1,035,000 through the issuance of up to 11,500,000 units, each priced at $0.09, comprising one common share and one-half common share purchase warrant [1] - Each warrant will be exercisable at $0.12 for a period of 24 months post the closing date [1] - The net proceeds from the private placement will be used to commence a drilling program at the Esquilache Project in Peru and for general working capital purposes [2] Group 2 - The closing of the private placement is subject to necessary corporate and regulatory approvals, including approval from the TSX Venture Exchange [3] - All securities issued will be subject to a hold period of four months plus a day from the date of issuance [3] - Carlton Precious Inc. is a publicly traded exploration company focused on precious and base metals, with projects in key mining jurisdictions including Peru and Australia [5]

Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of $0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].

Core Points - AlphaGen Intelligence Corp. announced a non-brokered private placement offering of up to 2,437,500 units at a price of $0.08 per unit, aiming for gross proceeds of up to $195,000 [1][3] - Each unit consists of one common share and one whole share purchase warrant, with the warrant convertible into an additional share at an exercise price of $0.12 for two years [2] - The net proceeds from the offering will be used for general working capital purposes, and the offering is expected to close around May 16, 2025, pending regulatory approvals [3] Company Overview - AlphaGen Intelligence Corp. is publicly traded and holds a portfolio in gaming, entertainment, eCommerce, and retail [5] - The company operates units such as Shape Immersive, a metaverse studio, and MANA, a SaaS solution for community engagement [5] - Notable clients and partners include RTFKT, Olympics, Red Bull, Intel, and TED [5]

Company Overview - Dogness (International) Corporation is a developer and manufacturer of a comprehensive line of Dogness-branded, OEM, and private label pet products [1] - The company was founded in 2003 with a focus on enhancing the relationship between pets and their caregivers through smart products, hygiene products, health and wellness products, and leash products [4] - Dogness has over 200 patents and patents pending, ensuring industry-leading quality through a fully integrated vertical supply chain and world-class research and development capabilities [4] Private Placement Details - Dogness announced a private placement transaction for US$6.0 million in gross proceeds from the sale of 1,200,000 Class A common shares at US$5.00 per share [1] - The shares are being sold to certain non-U.S. purchasers in a transaction exempt from registration under the Securities Act of 1933, relying on Regulation S [2] - Closing of the private placement is subject to customary closing conditions [2]

Company Overview - Southern Cross Gold Consolidated Ltd (TSXV: SXGC) (ASX: SX2) has successfully closed the first tranche of its private placement, raising C$88,799,220 through the issuance of 19,733,160 common shares and Chess Depositary Interests (CDIs) at a price of C$4.50 (A$5.10) per share [1][2][4] Placement Details - The first tranche of the placement involved the issuance of 16,171,050 CDIs and 3,562,110 common shares, with gross proceeds of A$82,472,355 and C$16,029,495 respectively [5][8] - A second tranche is anticipated to close around May 14, 2025, aiming for additional gross proceeds of approximately C$54,308,502 [4] Use of Proceeds - The net proceeds from the placement are earmarked for key milestones in the development of the Sunday Creek Gold-Antimony Project, including: - C$53 million for drilling to establish an Inferred Resource by Q1 2027 - C$27 million for decline development to enhance access to mineralization - C$4 million for a Preliminary Economic Assessment - C$59 million for exploration target expansion and working capital over three years [9] Project Significance - The Sunday Creek project, located 60 km north of Melbourne, Australia, is recognized as a significant gold and antimony discovery, with a mineralization structure extending over 12 km [13][14] - The dual-metal profile of the project, with antimony contributing 20% of the in-situ value, positions it strategically in light of China's export restrictions on antimony, a critical metal for defense and semiconductor applications [14] Insider Participation - Mr. Darren Morcombe, an insider of the company, subscribed for 980,392 CDIs under the first tranche, increasing his total holdings to 28,991,112 common shares, representing approximately 11.91% of the outstanding shares [11][12]

Core Viewpoint - Abcourt Mines Inc. has successfully closed an additional tranche of its non-brokered private placement, raising a total of $9,281,044 to support the restart of the Sleeping Giant mine and for general corporate purposes [1][4]. Group 1: Private Placement Details - The recent tranche raised gross proceeds of $4,613,004, contributing to a total of $9,281,044 raised through private placements [1]. - The private placement consists of units priced at $0.05 each, with each unit comprising one common share and one warrant [2][9]. - Each warrant allows the holder to purchase one common share at a price of $0.08 for a period of 36 months following the closing date [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to restart the Sleeping Giant mine and mill, along with working capital and general corporate purposes [4]. Group 3: Related Party Transactions - The private placement involved related party transactions, with insiders purchasing a total of 20,000,000 units [5][11]. - The Corporation relied on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's value being below 25% of the Corporation's market capitalization [5]. Group 4: Securities and Regulatory Compliance - All securities issued in connection with the private placement are subject to a restricted period of four months plus one day from the issuance date [6]. - The private placement remains subject to final approval from the TSX Venture Exchange [10].

Core Viewpoint - GD Culture Group Limited has successfully closed a private placement, raising approximately $5.5 million to support its working capital needs [3]. Group 1: Private Placement Details - The company sold an aggregate of 1,115,600 shares of common stock at a price of $0.524 per share and pre-funded warrants to purchase up to 9,380,582 shares at a price of $0.523 per warrant [2]. - The gross proceeds from the offering amounted to approximately $5.5 million, which will be utilized for working capital purposes [3]. Group 2: Company Overview - GD Culture Group Limited operates primarily through its subsidiaries, AI Catalysis Corp. and Shanghai Xianzhui Technology Co, Ltd., and is planning to enter the livestreaming market focused on e-commerce [7]. - The company’s main business activities include AI-driven digital human technology and live-streaming e-commerce [7].

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, May 05, 2025 (GLOBE NEWSWIRE) -- Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) is pleased to announce that it has closed the previously announced “best-efforts” private placement (the “Offering”) for total gross proceeds of $8.0 million, which includes the exercise in full of the over-allotment option. In connection with the Offering, the Company issued an aggregate of ...

Core Viewpoint - GD Culture Group Limited announced a private placement to raise approximately $5.5 million through the sale of common stock and pre-funded warrants [1][2]. Group 1: Private Placement Details - The company signed a private placement agreement on May 2, 2025, for the purchase of 1,115,600 shares of common stock at a price of $0.524 per share [1]. - Additionally, pre-funded warrants to purchase up to 9,380,582 shares of common stock were included in the offering at a price of $0.523 per warrant [1]. - The gross proceeds from the offering are expected to be around $5.5 million, which will be used for working capital purposes [2]. Group 2: Company Overview - GD Culture Group Limited operates primarily through its subsidiaries, including AI Catalysis Corp., and is focused on entering the livestreaming market with an emphasis on e-commerce [5]. - The company's main business activities involve AI-driven digital human technology and live-streaming e-commerce [5].

Core Points - Marvel Biosciences Corp. has successfully closed the second tranche of its non-brokered private placement, raising gross proceeds of $18,750 from the issuance of 150,000 units at a price of $0.125 per unit [1][2] - The proceeds from the offering will be allocated towards drug formulation, toxicology studies, and general working capital [5] - The company has clarified that no finders' fees or warrants were paid to Abinvest Corporation and Abingdon Capital Corp. as previously reported [3] Offering Details - The second tranche of the offering involved the issuance of 150,000 units, each consisting of one common share and one warrant [2] - Finders' fees of $1,312.50 were paid in cash, along with the issuance of 10,500 finder's warrants, which are exercisable at $0.175 per share for two years [2] - The offering is limited to accredited investors and is subject to approval by the TSX Venture Exchange [4] Company Overview - Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company [7] - The company is developing MB-204, a novel fluorinated derivative of the anti-Parkinson's drug Istradefylline, which may also have applications in treating other neurological diseases [7][9] - The company is exploring the potential of MB-204 in addressing neurodevelopmental disorders such as autism, depression, Alzheimer's Disease, Rett Syndrome, and Fragile X Syndrome [9]